Low-dose aprotinin in heart valve reoperations

Journal of Heart Valve Disease

Volumn 10, Issue 2, 2001, Pages 222-227

  Kirzner, C F ^a   Correia, A R ^a   Azevedo O M , Jr ^a   Maranhao M V ^a   Goncalves J R C ^a   Kirzner, M S M ^a   Xavier, A P R ^a   Figueiroa, J N ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APROTININ; CREATININE; HEMOGLOBIN; HEMOSTATIC AGENT; HEPARIN; PROTAMINE;

ADULT; ALLERGIC REACTION; ANESTHESIA INDUCTION; ARTICLE; BRADYCARDIA; BRONCHOSPASM; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; HEART SURGERY; HEART VALVE SURGERY; HEMOSTASIS; HUMAN; HYPOTENSION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REOPERATION;

ADULT; APROTININ; FEMALE; HEART VALVE DISEASES; HEART VALVES; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE; REOPERATION;

EID: 0035078062     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Resternotomy for bleeding after cardiac operation: A marker for increased morbidity and mortality
2. Fifteen hundred coronary reoperations: Results and determinants of early and late survival
3. Re-exploration for hemorrhage following coronary artery bypass grafting: Incidence and risk factors
4. Perioperative approaches to coagulation defects
5. Aprotinin in perspective
6. Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass
7. Meta-analysis of prophylactic drug treatment in the prevention of postoperative bleeding
8. Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery
9. Aprotinin versus desmopressin for patients undergoing operations with cardiopulmonary bypass. A double-blind placebo-controlled study
10. Comparaison des effets de l'aprotinin et de l'acid tranexamique sur le saignement en chirurgie cardiaque
11. Hemostatic effect of dipyridamole, tranexamic acid and aprotinin in coronary bypass grafting
12. Cost/benefit analysis of pharmacological hemostasis
13. Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: Aprotinin vs. tranexamic acid vs. epsilon aminocaproic acid
14. Fibrinolysis-adjusted perioperative low-dose aprotinin reduces blood loss in bypass operations
15. Aprotinin versus lysine analogues: The debate continues
16. Aprotinin: An update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery
17. High-dose aprotinin therapy: A review of the first five year's experience
18. Aprotinin: A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery
19. Developmental aspects of aprotinin
20. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass
21. Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery? A meta-analysis
22. High-dose aprotinin in cardiac surgery: Three years' experience in 1,784 patients
23. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets
24. Antifibrinolytiques et prévention du saignement en chirurgie cardiaque valvulaire. Comparaison de l'acide tranexamique à l'aprotinine à haute dose
25. Experience with low dose aprotinin
26. The effect of 'high dose' aprotinin and other factors on bleeding and revisions for bleeding in adult coronary and valve operations: An analysis of 2190 patients during a five-year period (1987-1991)
27. Aprotinin in primary valve replacement and reconstruction: A multicenter double-blind, placebo-controlled trial
28. Is aprotinin indicated for reoperative valvular surgery?
29. Beneficial effect of both tranexamic acid and aprotinin on blood loss reduction in reoperative valve replacement surgery
30. Preoperative platelet dysfunction increases the benefit of aprotinin in cardiopulmonary bypass
31. Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study
32. Aprotinin prevents cardiopulmonary bypass-induced platelet dysfunction. A scanning electron microscope study
33. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood
34. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting
35. Aprotinin for primary coronary artery bypass grafting: A multicenter trial of three dose regimens
36. Low-dose and high-dose aprotinin improve hemostasis in coronary operations
37. Randomized placebo-controlled double-blind study of three aprotinin regimens in primary cardiac surgery
38. Treasure T. Aprotinin therapy in cardiac operations: A report on use in 41 cardiac centers in the United Kingdom
39. Antigenicity of protamine and aprotinin in cardiac surgery
40. Prevalence of anaphylactic reactions to aprotinin: Analysis of two hundred forty-eight reexposures to aprotinin in heart operations
41. High-dose aprotinin in cardiac surgery: A prospective, randomized study
42. Aprotinin for coronary artery bypass grafting: Effect on postoperative renal function
43. A risk-benefit assessment of aprotinin in cardiac surgical procedures
44. The efficacy and safety of aprotinin use in cardiac surgery
45. Analyses of coronary graft patency after aprotinin use: Results from the international multicenter aprotinin graft patency experience (IMAGE) trial
46. Effect of aprotinin on need for blood loss transfusion after repeat open-heart surgery
47. High dose aprotinin to reduce blood loss in patients undergoing redo open heart operation